CTRP Terminology
CTRP Agent Terminology
S-equol
(-)-Equol
(3S)-3,4-dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol
2H-1-benzopyran-7-ol, 3,4-Dihydro-3-(4-hydroxyphenyl)-, (3S)-
2T6D2HPX7Q
531-95-3
768802
768802
768802
An orally bioavailable, non-steroidal estrogen naturally produced by the metabolism of the isoflavonoid daidzein by human intestinal microflora, with potential chemoprotective and estrogen receptor (ER) modulating activities. S-equol preferentially binds to and activates the beta isoform of ER in certain target tissues, while having an antagonistic effect in other tissues. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, affect vasomotor symptoms, and may decrease the proliferation rate of susceptible cancer cells. In addition, this agent interferes with the activity of enzymes involved in steroid biosynthesis. S-equol inhibits dihydrotestosterone (DHT) production and may inhibit the proliferation of androgen-driven prostate cancer. S-equol is the biologically active enantiomer while R-equol is essentially inactive and has a weak affinity for alpha-ER.
C120313
C3896945
CTRP
EQUOL
FDA
GDC
Pharmacologic Substance
S-equol
S-equol
S-equol
S-equol
NCIt Antineoplastic Agent Terminology
GDC Terminology
GDC Therapeutic Agent Terminology
NCI Drug Dictionary Terminology
GDC Value Terminology
Pharmacologic Substance
Non-Steroidal Estrogen
Estrogen Receptor Beta
FDA Established Names and Unique Ingredient Identifier Codes Terminology